Clinical Research

At CLS Health, we are striving to bring new and advanced treatment opportunities to our patients.

For more than 12 years the physicians of CLS Health have partnered with over 100 clinical trials to aid in the development or new treatment options for our patients. Study visits are conducted within the comfort of our practice office(s) with our partner Tranquil Clinical Research. Together, our Clinical Research Trials are research studies designed to test the safety and effectiveness of new medications and treatments.

 

Currently Enrolling Studies

enVISion Research Study

The enVISion study is evaluating the safety and effectiveness of an investigational drug called VIS649 for Immunoglobulin A Nephropathy (IgAN). Around 144 people in about 15 countries will participate in this research study.

Qualifications: 

  •  Are at least 18 years of age
  • Have been diagnosed with IgAN (confirmed by a kidney biopsy)
  • Have been taking a stable, maximally tolerated dose of certain blood pressure medications for the last 3 months (or are unable to tolerate these medications)
  • Have not taken systemic corticosteroids or medications that suppress your body’s immune system in the last 16 weeks
  • Are willing and able to use study-provided supplies to collect your urine for 24 hours and then return it to the study nurse

Requires:

  • Other criteria will be reviewed at the first study visit to determine if you are able to participate in the study

Contact Us NOW Space is Limited:

  • Tranquility Research
  • Call 713-907-6054
  • There will be compensation for your time

Click here for more information regarding this study or call 713-907-6054

enVISion Research Study Information

————————————————————————————————————————————-

Lung Bio Study

Diagnosed with pulmonary hypertension due to chronic obstructive pulmonary disease (PH-COPD)?

Qualifications: 

  • Be 18 or older
  • Must have an established diagnosis of chronic obstructive pulmonary disease (COPD) with suspected or confirmed pulmonary hypertension
  • Must be able to walk at least 100 meters during a 6-minute walk test without limitations in mobility using no oxygen, or oxygen at no more than 10 liters per minute
  • Willing and able to use Sponsorprovided devices (actigraph, spirometer, and smart device)

Requires:

  • Inhaled Treprostinil for PH-COPD
  • Willing to undergo Right Heart Catherization

Contact Us NOW Space is Limited:

  • Tranquility Research
  • Call 713-907-6054
  • There will be compensation for your time

Click here for more information regarding this study or call 713-907-6054

Lung Bio PERFECT Study Information

————————————————————————————————————————————-

FSGS Study

FSGS is a type of kidney disease that occurs when scar tissue develops on the parts of your kidneys that act as filters (the glomeruli). The scar tissue makes it more difficult for the filters to do their job. Instead of keeping essential proteins in your body, the injured filters allow these proteins to flow into the urine. This can lead to high levels of protein in your urine, a condition called proteinuria.
Podocytes are cells lining the kidney that, in their normal state, prevent proteinuria. Injury to, and loss of, podocytes is a central component of FSGS. Protecting podocytes from further injury, and stopping proteinuria, may help slow the progression of kidney disease and potentially prevent kidney failure.
What is the purpose of this trial?
Currently, there is no approved therapy in the US to treat Focal Segmental Glomerulosclerosis (FSGS). Advances in drug therapy are key to treating FSGS in its early stages and preventing further kidney damage. The TRACTION-2 Trial is testing an investigational medication (GFB-887) that has the potential to reduce the amount of protein in urine and preserve kidney function in patients with kidney disease. If you have FSGS, this trial may be an option for you.

Qualifications: 

  • Are 18 to 75 years of age
  • Have been diagnosed or are being treated for FSGS
  • Have high levels of protein in your urine (proteinuria)

Requires:

  • Diagnosis based on documented biopsy or genetic testing and currently receiving ACE inhibitor or ARB for 3 months

Contact Us NOW Space is Limited:

  • Tranquility Research
  • Call 713-907-6054
  • There will be compensation for your time

Click here for more information regarding this study or call 713-907-6054

FSGS Study Information

————————————————————————————————————————————-

Over Active Bladder Study

Diagnosed with OAB? Participate in a clinical study for a new wearable OAB device

Qualifications: 

  • Be 18 or older
  • Diagnosed with Overactive Bladder
  • Have an average of 10 urinary frequency events per day
  • Have daily access to WIFI

Requires:

  • Wearing an investigational device for 30 minutes 1 to 3 times per week in your home
  • 12-week study period

Contact Us NOW Space is Limited:

  • Tranquility Research
  • Call 713-907-6054
  • There will be compensation for your time

Click here for more information regarding this study or call 713-907-6054

Over Active Bladder Clinical Study Information

————————————————————————————————————————————-

Infant Research Study

Have you been switching your baby’s formula often? Before switching again, please consider the following:

Dr. Palmer at Clear Lake Pediatrics is looking for fussy babies to participate in a 1 month investigational formula research study.

Qualifications: 

  • Full-term, healthy newborns who are 7-42 days of age
  • Babies who being exclusively formula-fed

Participation Includes:

  • Study visits at no cost to you
  • Study formula provided at no cost
  • Compensation for your time will be provided

Contact Us NOW Space is Limited:

  • Tranquility Research
  • Call 713-907-6054
  • There will be compensation for your time

Click here for more information regarding this study or call 713-907-6054

Infant Research Study Information

How to Participate

Participants undergo careful pre-screening and screening steps before they are enrolled in a study. Screening for criteria like age, previous treatments, and other medical conditions are among the screening criteria used to protect a participant’s safety and to ensure researchers obtain the information they need.

Eligible participants meet with one of our trained research coordinator staff to review the study and answer all questions. A document called an informed consent that has been approved by an independent review board (IRB) is reviewed and signed prior to any data collection or testing for the study.

In most cases, participation in a clinical trial incurs no cost to the patient. Sponsors may also offer compensation for time and travel. This information will be discussed during the informed consent review.

Study participation is voluntary. Participants have the right to withdraw from study participation at any time. The decision to withdraw will not result in any penalty nor adversely affect your relationship with your study doctor or practitioner.

 

Study Links

Over Active Bladder

Click here for more information regarding this study or call 713-907-6054

AMHOAB_Advert_12Apr2021

 

Infant Research Study

Click here for more information regarding this study or call 713-907-6054

Abbott_Advertisement_IBR_Approved